Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma

Head & Neck ◽  
2008 ◽  
Vol 30 (9) ◽  
pp. 1216-1223 ◽  
Author(s):  
Frank J. P. Hoebers ◽  
Frank A. Pameijer ◽  
Josien de Bois ◽  
Wilma Heemsbergen ◽  
Alfons J. M. Balm ◽  
...  
Keyword(s):  
Head And Neck ◽  
Primary Tumor ◽  
Prognostic Value ◽  
Low Dose ◽  
Tumor Volume ◽  
Head And Neck Carcinoma ◽  
Concurrent Chemoradiation ◽  
Advanced Stage ◽  
Primary Tumor Volume ◽  
Neck Carcinoma

Concurrent chemoradiation with daily low dose cisplatin for advanced stage head and neck carcinoma

2007 ◽  
Vol 85 (1) ◽  
pp. 42-47 ◽  
Author(s):  
Frank J.P. Hoebers ◽  
Wilma Heemsbergen ◽  
Alfons J.M. Balm ◽  
Mathilde van Zanten ◽  
Jan H. Schornagel ◽  
...  
Keyword(s):  
Head And Neck ◽  
Low Dose ◽  
Head And Neck Carcinoma ◽  
Concurrent Chemoradiation ◽  
Advanced Stage ◽  
Neck Carcinoma

Sarcopenia at the infrahyoid level as a prognostic factor in patients with advanced-stage non-virus-related head and neck carcinoma

2021 ◽  
Author(s):  
Daisuke Yunaiyama ◽  
Mitsuru Okubo ◽  
Eri Arizono ◽  
Kiyoaki Tsukahara ◽  
Maki Tanigawa ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Head And Neck ◽  
Head And Neck Carcinoma ◽  
Advanced Stage ◽  
Neck Carcinoma

scholarly journals Automatic segmentation of head and neck primary tumors on MRI using a multi-view CNN

2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Jens P.E. Schouten ◽  
Samantha Noteboom ◽  
Roland M. Martens ◽  
Steven W. Mes ◽  
C. René Leemans ◽  
...  
Keyword(s):  
Head And Neck ◽  
Treatment Planning ◽  
Primary Tumor ◽  
Tumor Volume ◽  
Automatic Segmentation ◽  
Neck Region ◽  
Primary Tumors ◽  
Head And Neck Region ◽  
Primary Tumor Volume ◽  
Mri Sequences

Abstract Background  Accurate segmentation of head and neck squamous cell cancer (HNSCC) is important for radiotherapy treatment planning. Manual segmentation of these tumors is time-consuming and vulnerable to inconsistencies between experts, especially in the complex head and neck region. The aim of this study is to introduce and evaluate an automatic segmentation pipeline for HNSCC using a multi-view CNN (MV-CNN). Methods The dataset included 220 patients with primary HNSCC and availability of T1-weighted, STIR and optionally contrast-enhanced T1-weighted MR images together with a manual reference segmentation of the primary tumor by an expert. A T1-weighted standard space of the head and neck region was created to register all MRI sequences to. An MV-CNN was trained with these three MRI sequences and evaluated in terms of volumetric and spatial performance in a cross-validation by measuring intra-class correlation (ICC) and dice similarity score (DSC), respectively. Results The average manual segmented primary tumor volume was 11.8±6.70 cm3 with a median [IQR] of 13.9 [3.22-15.9] cm3. The tumor volume measured by MV-CNN was 22.8±21.1 cm3 with a median [IQR] of 16.0 [8.24-31.1] cm3. Compared to the manual segmentations, the MV-CNN scored an average ICC of 0.64±0.06 and a DSC of 0.49±0.19. Improved segmentation performance was observed with increasing primary tumor volume: the smallest tumor volume group (<3 cm3) scored a DSC of 0.26±0.16 and the largest group (>15 cm3) a DSC of 0.63±0.11 (p<0.001). The automated segmentation tended to overestimate compared to the manual reference, both around the actual primary tumor and in false positively classified healthy structures and pathologically enlarged lymph nodes. Conclusion An automatic segmentation pipeline was evaluated for primary HNSCC on MRI. The MV-CNN produced reasonable segmentation results, especially on large tumors, but overestimation decreased overall performance. In further research, the focus should be on decreasing false positives and make it valuable in treatment planning.

Role of neck dissection following concurrent chemoradiation for advanced head and neck carcinoma

Head & Neck ◽  
2006 ◽  
Vol 28 (12) ◽  
pp. 1099-1105 ◽  
Author(s):  
Véronique-Isabelle Forest ◽  
Phuc Félix Nguyen-Tan ◽  
Jean-Claude Tabet ◽  
Marie-Jo Olivier ◽  
Daniel Larochelle ◽  
...  
Keyword(s):  
Head And Neck ◽  
Neck Dissection ◽  
Head And Neck Carcinoma ◽  
Concurrent Chemoradiation ◽  
Advanced Head ◽  
Neck Carcinoma

Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma.

1994 ◽  
Vol 12 (5) ◽  
pp. 946-953 ◽  
Author(s):  
S G Urba ◽  
A A Forastiere ◽  
G T Wolf ◽  
R M Esclamado ◽  
P W McLaughlin ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck ◽  
Primary Tumor ◽  
Organ Preservation ◽  
Response Rate ◽  
Head And Neck Carcinoma ◽  
Complete Response ◽  
Tumor Site ◽  
Primary Tumor Site ◽  
Neck Carcinoma

PURPOSE We designed a protocol to evaluate the possibility of organ preservation in patients with advanced, resectable carcinoma of the head and neck. The regimen consisted of intensive chemotherapy followed by radiation therapy alone for patients with good response to treatment. The end points of the study were response rate, organ preservation, toxicity, and survival. PATIENTS AND METHODS Forty-two eligible patients with carcinoma of the oral cavity, oropharynx, hypopharynx, larynx, and paranasal sinuses were enrolled. Induction chemotherapy consisted of three cycles of mitoguazone, fluorouracil (5-FU), and high-dose continuous infusion cisplatin. Patients who had a complete response to chemotherapy, or whose tumor was downstaged to T1N1, were treated with definitive radiation therapy, to a total dose of 66 to 73.8 Gy. Patients with residual disease greater than T1N1 underwent surgery and postoperative radiation. RESULTS The overall response rate to chemotherapy was 84%, with a 43% complete response rate, and a 68% complete response rate at the primary tumor site. Sixty-nine percent of patients (29 of 42) were initially spared surgery to the primary tumor site, and four of these patients (14%) required neck dissection only, after radiation therapy. These tumor sites included oral cavity, oropharynx, hypopharynx, larynx, and sinuses. Eventually, five of these patients (17%) required salvage surgery and eight patients (28%) had unresectable or metastatic relapses. With a median follow-up duration of 38.5 months, 36% of all patients have had preservation of the primary tumor site and remain disease-free. The median survival duration is 26.8 months. Toxicity was substantial, with a 70% incidence of grade 3 to 4 granulocytopenia and two septic deaths. CONCLUSION Organ preservation without apparent compromise of survival was achieved in patients with selected nonlaryngeal sites of head and neck carcinoma. Larger site-specific trials with less toxic regimens conducted in randomized fashion are required to extend these data.

Lack of effect of palifermin on the anti-tumor activity of cisplatin, cetuximab or panitumumab in the FaDu human head and neck carcinoma model

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 6060-6060
Author(s):  
L. Borges ◽  
R. Brake ◽  
R. Radinsky ◽  
C. Starnes
Keyword(s):  
Head And Neck ◽  
Tumor Volume ◽  
Xenograft Model ◽  
Head And Neck Carcinoma ◽  
Human Head ◽  
Therapeutic Modalities ◽  
Pharyngeal Carcinoma ◽  
Neck Carcinoma ◽  
Significant Difference ◽  
Anti Tumor Activity

6060 Background: The FaDu human pharyngeal carcinoma cell line expresses the receptors for both KGF and EGF. Palifermin is a recombinant form of human KGF. The objective of this study was to determine whether the combination of palifermin with cisplatin and the EGFR inhibitors cetuximab or panitumumab interferes with the anti-tumor activities of these agents in the FaDu head and neck xenograft model. Methods: FaDu tumor cells were implanted subcutaneously in CD1 nude mice. For the combination of palifermin with cetuximab and cisplatin, treatment began on day 9 and for the combination of palifermin with panitumumab and cisplatin, treatment began on day 10. The primary endpoint was the measure of tumor volume. Results: There was no statistically significant difference in tumor volume between the control arm and palifermin alone (p = 0.9993, 0.9831). Neither was there a statistically significant difference between the combination of palifermin, cisplatin and cetuximab compared to the combination of cisplatin and cetuximab (p = 0.7730). Similarly, there was no significant difference between the combination of palifermin, cisplatin and panitumumab compared to the combination of cisplatin and panitumumab (p = 0.9739). Conclusions: In drug combination settings, the addition of palifermin did not affect the therapeutic efficacy of cisplatin, cetuximab or panitumumab in any of the two- or three-way drug combinations. When used alone, palifermin did not promote the growth of the FaDu human xenograft despite the fact that these tumors express KGFR. The lack of interference of palifermin with the anti-tumor activity of cisplatin and the anti-EGFR target therapeutics suggests it is appropriate to move forward clinically investigating the use of palifermin in solid tumor settings in which these therapeutic modalities are used. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document